Natco Pharma Under USFDA Lens – What You Need to Know? Explained.

Natco Pharma is in focus after the USFDA (US drug regulator) completed inspections at its two facilities in Hyderabad. What happened? From June 9–19, the USFDA inspected Natco’s formulation unit at Kothur. After the visit, Natco received 7 observations (points needing correction) in Form 483. Natco has assured that it will resolve these issues quickly within the required time. Earlier update: On June 13, USFDA also inspected Natco’s API unit (raw material plant) at Mekaguda. That visit ended with just 1 observation. What is Form 483? Form 483 is a report issued by the USFDA when they spot problems during inspections. It doesn’t mean a ban or shutdown — it’s a warning to fix things. What Natco said: They're confident about fixing all issues. They're committed to quality and global standards like cGMP (Good Manufacturing Practices). Stock Snapshot: 52-week High: ₹1,638.35 (Sep 2024) 52-week Low: ₹660.05 (Apr 2025) Currently, the stock is 46% below its high and 33% above its low. Market Cap: ₹15,785 Cr What should investors know? USFDA observations are common in pharma. If Natco resolves them on time, the long-term impact may be limited. Keep an eye on company updates.